
    
      Upon determination of eligibility, all patients will receive:

      Fludarabine + Rituximab + CAMPATH-1H

      Patients who are judged by the investigator not to be candidates for fludarabine due to
      advanced age, marginal performance status or coexistent medical conditions will receive
      rituximab alone followed by CAMPATH-1H.
    
  